Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update.
Alzheimers Res Ther
; 16(1): 177, 2024 Aug 01.
Article
en En
| MEDLINE
| ID: mdl-39090680
ABSTRACT
Since 2014, sacubitril/valsartan (Entresto®) is widely prescribed for heart failure. Despite neprilysin inhibition's benefits in heart failure, concerns about potential amyloid-beta (Aß) accumulation and Alzheimer's disease (AD) risk have persisted. This narrative review, a decade post-approval, evaluates the risk of amyloid pathology and neurocognitive disorders in long-term sacubitril/valsartan use. Clinical trials, real-world studies, and pharmacovigilance data do not indicate an increased risk of cognitive decline. In patients treated with sacubitril/valsartan blood-based amyloid biomarkers show perturbations, while neuroimaging biomarkers reveal no significant increase in amyloid load. Despite a theoretical risk of amyloid accumulation and AD under treatment with sacubitril/valsartan, current clinical data appears reassuring, and there is no signal indicating an increased risk of cognitive decline, but a perturbation of amyloid blood-based biomarkers, which implies great caution when interpreting biomarkers in this context.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tetrazoles
/
Compuestos de Bifenilo
/
Combinación de Medicamentos
/
Antagonistas de Receptores de Angiotensina
/
Enfermedad de Alzheimer
/
Valsartán
/
Aminobutiratos
Límite:
Humans
Idioma:
En
Revista:
Alzheimers Res Ther
Año:
2024
Tipo del documento:
Article
País de afiliación:
Francia
Pais de publicación:
Reino Unido